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OBJECTIVES: The Recent ISPOR Task Force on Modelling emphasised the 
importance of conceptualising and validating models. We report a new model of 
COPD that has been founded on a conceptual model designed by a panel of 
experts prior to data analysis, implemented using a novel linked-equation 
approach and internally validated with the data used to generate the model 
parameters. METHODS: An expert panel, including clinicians and decision 
modellers with experience of COPD, developed a conceptual model including 
causal relationships between core components of the disease (lung function, 
exacerbations, symptoms and exercise capacity) and final health outcomes and 
resource use (survival, quality of life, cost). Risk equations describing these 
relationships were estimated from a three-year longitudinal study (ECLIPSE), 
with bi-directional relationships in the conceptual model handled by using 
lagged variables. The model was implemented as a linked-equation model 
enabling direct estimation of health service costs and quality adjusted life-years 
for cohorts of COPD patients over a lifetime time horizon. Internal validation was 
undertaken by comparing three years of predicted cohort experience with results 
reported for ECLIPSE. RESULTS: At three years, the model predicted a survival 
rate of 90.7%, an average annual exacerbation rate of 0.95 and an annual FEV1 
decline of 38.8ml per year, which all fell within the confidence limits of the 
original ECLIPSE data. Projections of the risk equations over time permitted 
extrapolation to patient lifetimes. Potential treatment effects on intermediate 
risk factors lead to predicted effects on final model outcomes. CONCLUSIONS: 
We have conceptualised, implemented and internally validated a new form of 
model for COPD based on a series of linked equations. This model is capable of 
predicting COPD outcomes for a variety of potential treatment effects on 
intermediate risk factors. Further validation of short and long-term predictions 
of the model is required.  
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OBJECTIVES: Fixed combinations of inhaled corticosteroids and long-acting β2-
agonists are frequently used to reduce exacerbations for patients with chronic 
obstructive pulmonary disease (COPD), but some treatments with inhaled 
glucocorticosteroids are linked with increased risk of pneumonia. The objective of 
this study was to evaluate the cost-effectiveness of budesonide/formoterol relative 
to fluticasone/salmeterol based on both real-world effectiveness and safety data 
(NCT01146392) from a Swedish health care perspective. METHODS: Resource use, 
effectiveness and safety data were collected retrospectively from primary care 
medical records’ data for patients with a diagnosis of COPD (J44) and merged with 
Swedish hospital, drug, and cause of death register data from 01 January 1999 to 31 
December 2009. Propensity score matching on 31 variables two years pre-index was 
done at the index date (first prescription of fixed combination post COPD diagnosis) 
to minimize bias. The effectiveness variable was the number of exacerbations 
avoided. Exacerbations were defined as hospitalisations and emergency room visits 
for COPD, glucocorticosteroids prescriptions and/or antibiotics prescriptions for 
respiratory tract infections. Direct costs were calculated by applying year 2011 
Swedish unit costs to the annual resource use for exacerbations as well as 
pneumonia-related hospitalisations (J10-18). Bootstrapping and one-way sensitivity 
analyses were used to quantify uncertainty around estimates. RESULTS: The 
annual exacerbation rate and the average annual hospitalisation days 
(exacerbation- and/or pneumonia-related) were 0.80 and 0.87 for patients treated 
with budesonide/formoterol (n=2734) and 1.09 and 1.36 for patients treated with 
fluticasone/salmeterol (n=2734, 27% and 36% reduction respectively, p<0.0001). 
Treatment with budesonide/formoterol was cost-saving compared with 
fluticasone/salmeterol (total average annual cost per patient was SEK 12,495 [€1384] 
and SEK 16,301 [€1805], respectively). Sensitivity analyses showed that results were 
robust. CONCLUSIONS: Budesonide/formoterol was the dominant strategy (more 
effective at lower cost) compared to fluticasone/salmeterol for the treatment of 
patients with COPD based on real-world effectiveness and safety data.  
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OBJECTIVES: Ventilator-associated pneumonia (VAP) is associated with 
increasing intensive care unit (ICU) admissions, morbidity and length of stay 
(LOS) as it’s one of the most common nosocomial infections in the ICU; raising 
overall costs. Literature suggests costs could be significantly reduced by using 
the most efficient empiric therapy. The aim of this study was to assess the cost-
effectiveness (CE) of linezolid against generic vancomycin as an empiric therapy 
for adult VAP patients, from the public health care perspective. METHODS: A 
cohort of patients with VAP in the ICU was simulated using a decision-tree 
model to compare costs and effectiveness of linezolid (600 mg/12 hours) and 
vancomycin (15 mg/kg/12 hours) (basecase). Effectiveness measures were: 
microbiological success rates, mortality rates, and ICU and ward LOS. The model 
used a 12-week time horizon and only direct medical costs were considered 
(inpatient costs, medication expenses, adverse events costs, hematologic and 
gastrointestinal tests) Effectiveness and epidemiologic data were retrieved from 
published literature. Local costs (2012 US$) were gathered from the Social 
Security of Guatemala official databases. Monte Carlo probabilistic sensitivity 
analysis (PSA) was constructed. RESULTS: Linezolid resulted as the most 
effective and less expensive option for VAP adult patients. Clinical success rate 
was higher with linezolid (64.4%) against vancomicyn (56.1%). Mean expected 
ICU LOS was 18 days for linezolid and 22 days for vancomycin, ward LOS was 9 
and 10 days with linezolid and vancomycin, respectively. Mortality rate was 
found lower in the linezolid arm (10.13%) in comparison to vancomycin (15.74%). 
Overall costs per patient were $23,089.15 with linezolid and $26,384.63 with 
vancomycin. In the CE incremental analysis, linezolid appeared as the cost-
saving option. PSA outcomes support the robustness of these findings. 
CONCLUSIONS: Linezolid resulted as the cost-saving therapy for treating VAP 
adult patients in ICU in Guatemala.  
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OBJECTIVES: To quantify the potential US societal benefits, in terms of health 
care costs and quality of life, of improving gaps in care by increasing compliance 
with guideline-driven asthma management relative to the current level of care 
(i.e. status quo) METHODS: A Markov model of asthma was created to simulate 
the natural history of asthma and the potential impact of improved compliance 
to medications over a 20 year time horizon. The current state of asthma care 
(status quo) in terms of the proportion of individuals who receive regular, 
irregular, and no controller treatment, along with parameters representing the 
natural history of asthma, was estimated from the literature. Total costs, 
exacerbation rates, and quality-adjusted life years (QALY) of a status quo 
strategy was compared with a hypothetical situation in which each individual 
receives regular controller medications according to the current 
recommendations (ideal strategy). All costs and outcomes were discounted at a 
rate of 0.02. RESULTS: Under the status quo, each individual with asthma will 
generate, on average, US $9681 in total medical costs and 14.3 QALYs over 20 
years. By following guidelines, average total costs will increase to $18,446 
producing 14.6 QALYs. The discounted number of exacerbations over 20 years for 
the status quoand optimal strategies will be 10 and 4.6, respectively. The 
incremental cost-effectiveness ratio (ICER) of the ideal strategy compared to 
status quo was estimated to be $29,217 US per QALY gained. CONCLUSIONS: 
There is a significant opportunity to reduce the socio economic burden of 
asthma in the US with greater adherence to evidence-based asthma 
management guidelines. While improved adherence to guidelines increases 
some costs (e.g. medications), the substantial return on investment associated 
with improved adherence will likely offset the extra costs.  
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OBJECTIVES: Little information exists on the acute treatment provided for 
rhinosinusitis and its associated costs. This study assessed the cost-effectiveness of 
mometasone furoate versus amoxicillin for the treatment of rhinosinusitis in 
Mexico from a health care perspective. METHODS: A decision tree model was 
constructed using decision analytical techniques. Data sources included published 
literature, clinical trials, official price/tariff lists, and Delphi panel data. The 
comparators were mometasone furoate 200μg twice daily and amoxicillin 500mg 
three times daily. This study further do not included MFNS 200μg once daily as a 
treatment arm because it was not found to be superior to amoxicillin. The time 
horizon was 2 weeks. The effectiveness outcomes of the study were modeled as 
changes in the Major Symptom Score (MSS). MSS consists of five questions 
concerning rhinorrhoea, post-nasal drip, nasal congestion, sinus headache, and 
facial pain. Costs were valued in US dollar, year 2012 values. One-way and 
probabilistic sensitivity analyses were conducted to evaluate uncertainty in the 
results. RESULTS: The projected costs were US$ 258 with Mometasone furoate and 
$US 272 with.The benefits were 0.52 with Mometasone furoate, 0.45 with 
Amoxicilin. Mometasone furoate was associated with a cost savings per patient of 
US$ 13.92 versus amoxicillin over a period of 2 weeks from a health care 
perspective. The incremental cost-effectiveness ratio for Mometasone furoate 
dominated Amoxicilin. Sensitivity analysis confirmed the overall cost savings and 
gains in effectiveness. CONCLUSIONS: Our analysis suggests Mometasone Furoate 
improves health outcomes in a cost-effective manner compared with Amoxicilin, 
and highlights the importance of using evidence-based effectiveness estimates in 
economic studies of rhinosinusitis therapies  
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OBJECTIVES: The purpose of this research was to determine the cost-
effectiveness of budesonide/formoterol maintenance and reliever therapy of 
bronchial asthma in condition of Russian health care system. Total medical 
expenses and effectiveness in term of exacerbations prevention were compared 
for budesonide/formoterol maintenance and reliever therapy, 
